Pure Global
NCT05759052

Vincristine-induced Peripheral Neuropathy in Adult Survivors of Childhood and Adolescent Leukemia

Long-term Evaluation of Vincristine-induced Peripheral Neuropathy in Adult Survivors of a Multicenter Prospective Cohort of Childhood and Adolescent Leukemia (LEA Cohort): a Multicenter Cross-sectional Study
University Hospital, Clermont-Ferrand·ClinicalTrials.gov·behavioralNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Chemotherapy-induced Peripheral Neuropathy
Drug/Device/Intervention
self-administered questionnaire
Study type
Observational
Intervention type
behavioral
Sponsor & location
Primary sponsor
University Hospital, Clermont-Ferrand
Timeline & enrollment
Phase
N/A
Start date
Mar 01, 2023
End date
Jul 31, 2025
Enrollment
750 participants
Primary outcome

Sensitive chemotherapy-induced peripheral neuropathy

Summary

Vincristine is a major anticancer agent in the management of hematological malignancies. One
 of the main side effects is chemotherapy-induced peripheral neuropathy (CIPN). CIPN is a
 characteristic side effect of neurotoxic anticancer drugs. CIPN associated with vincristine
 is typically characterized by distal and symmetrical sensory symptoms (dysesthesia and
 paresthesia). Motor and vegetative symptoms can also be found. The prevalence of CIPN
 associated with vincristine during treatment ranges from 12 to 100% in children (depending on
 the endpoint).
 
 The aim of this cross-sectionnal study will be to explore the CIPN prevalence and severity in
 adult survivors of childhood leukemia and having been treated by vincristine.

ICD-10 classifications
Drug-induced polyneuropathyParaneoplastic neuromyopathy and neuropathyPolyneuropathy due to other toxic agentsIdiopathic peripheral autonomic neuropathyIdiopathic progressive neuropathy
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05759052
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05759052 through Pure Global AI's free database. This phase not specified trial is sponsored by University Hospital, Clermont-Ferrand and is currently Not yet recruiting. The study focuses on Chemotherapy-induced Peripheral Neuropathy. Target enrollment is 750 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.